| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K50799972 | CTRPv2 | pan-cancer | AAC | -0.031 | 0.4 |
| mRNA | ML239 | CTRPv2 | pan-cancer | AAC | -0.029 | 0.4 |
| mRNA | Doxorubicin | CTRPv2 | pan-cancer | AAC | -0.024 | 0.4 |
| mRNA | NVP-231 | CTRPv2 | pan-cancer | AAC | -0.026 | 0.4 |
| mRNA | CD-1530 | CTRPv2 | pan-cancer | AAC | -0.031 | 0.4 |
| mRNA | BMS-754807 | GDSC1000 | pan-cancer | AAC | 0.028 | 0.4 |
| mRNA | BRD-K11533227 | CTRPv2 | pan-cancer | AAC | 0.03 | 0.4 |
| mRNA | Nilotinib | CTRPv2 | pan-cancer | AAC | -0.03 | 0.4 |
| mRNA | KHS101 | CTRPv2 | pan-cancer | AAC | -0.03 | 0.4 |
| mRNA | salermide:PLX-4032 (12:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.03 | 0.4 |